Cardinal Health sees FY27 non-GAAP EPS of $12.40 to $12.60
Company expects FY27 Pharmaceutical and Specialty Solutions revenue growth of 3%-5%
Company expects FY27 Global Medical Products and Distribution revenue growth of 2%-4%
Overview
U.S. distributor's Q4 revenue rose 6% yr/yr but missed analyst expectations
Adjusted EPS for Q4 grew 40% and beat analyst expectations, aided by one-time tariff refund
Company completed $1.4 bln share repurchases in FY26, board authorized additional $5.0 bln
Result drivers
Pharmaceutical sales - Revenue and profit growth in Pharmaceutical and Specialty Solutions segment driven by brand and specialty pharmaceutical sales and positive generics program performance
Tariff refund impact - One-time IEEPA tariff refund boosted Q4 adjusted EPS and Global Medical Products and Distribution segment profit
Distribution volumes - Lower distribution volumes reduced Global Medical Products and Distribution segment revenue
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Cardinal Health, Inc. is $260.00, about 9.6% above its August 10 closing price of $237.18
The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 17 three months ago
CAH•
